Step-by-Step SCID Newborn Screening Protocol
Newborn screening for SCID uses TREC (T-cell receptor excision circle) quantification from dried blood spots, followed by a standardized algorithm for abnormal results that includes retesting, confirmatory flow cytometry, and urgent referral for definitive diagnosis and treatment. 1
Initial Screening (First-Tier)
Blood Collection and TREC Analysis:
- Obtain dried blood spot (DBS) from routine newborn screening card (typically 3.2mm punch, approximately 3 μL whole blood) 2
- Extract DNA and perform real-time quantitative PCR to measure TRECs 2, 3
- TRECs are byproducts of normal T-cell receptor gene recombination during thymic T-cell development—absent or very low TRECs indicate absent or severely reduced T-cell production 1
Interpreting Initial Results:
- Normal value: TRECs above cutoff (mean ~827, median ~708 per punch in normal newborns) 2
- Abnormal value: TRECs below cutoff without DNA amplification failure—this is your screen positive 1
- Incomplete: DNA amplification failure requiring immediate retest 1
Algorithm for Abnormal Results
Step 1: Retest on Same Card
- If initial result shows abnormal value, perform retest using the same NBS card (second punch from original sample—not returning to the newborn) 1
- This distinguishes technical issues from true positives
Step 2: New Sample Test (if retest confirms abnormal)
- Request new sample test: obtain fresh DBS from the newborn for repeat TREC analysis 1
- This is critical—you're going back to the infant for a new heel stick
- Retest rates typically 1.4-3.34% depending on cutoff values; requested second sample rate approximately 0.23% 4
Step 3: Urgent Referral
- If new sample confirms abnormal TRECs, immediately refer the infant to pediatric immunologist for diagnostic evaluation 1
- This is urgent—do not delay. SCID is a medical emergency 5
Confirmatory Diagnostic Workup
Upon referral, perform the following immediately:
Flow Cytometry (Essential First Step)
- Complete blood count with differential to assess for lymphopenia 5
- Lymphocyte subset enumeration: absolute counts of CD3+ T cells, CD4+ T cells, CD8+ T cells, CD19+ B cells, CD16/56+ NK cells 5
- Naive T-cell markers: CD45RA+ (naive) vs CD45RO+ (memory) T cells 5
- T-cell counts <1500/mm³ or naive cells <50% require further evaluation 5
- TCR αβ and TCR γδ expression 4
- HLA-DR+ activated T cells 4
Critical Distinction: Are T Cells Present?
If NO T cells present:
- Consistent with classic SCID 5
- Proceed to determine immunophenotype (T-B+NK+, T-B-NK+, T-B-NK-, etc.) to guide genetic diagnosis 5
If YES, T cells are present:
- Determine T-cell origin: Are these maternal T cells? 5
- Test for maternal cell engraftment (maternal T cells indicate SCID with maternal engraftment)
- If autologous T cells present, consider leaky SCID or non-SCID T-cell lymphopenia 5
Functional Testing
- In vitro T-cell proliferation to mitogens (PHA) and antigens 5
- NK cell cytotoxicity assay 5
- Immunoglobulin levels: IgG, IgA, IgM (may show hypogammaglobulinemia, though IgG can be normal from maternal transfer) 5
Genetic Testing
- Targeted gene sequencing or whole exome sequencing to identify specific molecular defect 5
- Over 20 genes can cause SCID 6
Classification of Diagnostic Outcomes
Use PIDTC criteria to define SCID 1
Confirmed SCID:
- Meets PIDTC classification criteria
- Includes classic SCID, leaky SCID, and Omenn syndrome 1
Non-SCID T-cell lymphopenia (TCL):
- Low T-cell numbers but doesn't meet SCID criteria
- Subdivide into:
Prematurity-related:
- Gestational age <37 weeks and/or birth weight <2500g with low T cells but no other explanation 1
- Premature infants have lower TRECs at birth that typically normalize over time 5
Normal T-cell subsets (False Positive):
- Normal age-appropriate T-cell counts and normal naive CD4+ cells on flow cytometry 1
Immediate Management Upon Positive Screen
While awaiting confirmatory testing, institute protective measures immediately:
Infection Prevention (Urgent)
- Avoid live vaccines (rotavirus, BCG, varicella) 1
- Protective isolation: avoid large crowds, sick contacts, daycare 5
- Hospital isolation if admitted 5
Prophylaxis
- PCP prophylaxis: Trimethoprim-sulfamethoxazole 5 mg/kg/day (trimethoprim component) orally 3 times per week 5
- Alternatives: pentamidine 5 mg/kg every 4 weeks, dapsone 1 mg/kg/day, atovaquone 30 mg/kg/day 5
- IgG replacement therapy: Initiate immediately for confirmed or suspected SCID 5
- Consider palivizumab during RSV season 5
Definitive Treatment
- Hematopoietic stem cell transplantation (HSCT) is curative and should be pursued urgently 5, 6
- Outcomes are age-dependent: transplantation within first 28 days of life shows significantly improved T-cell development; survival 95% if transplanted before 3.5 months vs 76% if later 5
- Gene therapy available for some SCID forms 6
Common Pitfalls to Avoid
Don't delay referral: SCID is a medical emergency. Infants can die from overwhelming infection at any time 5
Don't confuse terminology: "TREC positive" is ambiguous—use "abnormal value" for low TRECs and "normal value" for TRECs above cutoff 1
Don't dismiss prematurity alone: While premature infants have lower TRECs, they still require follow-up until values normalize 5
Don't give live vaccines: Even while awaiting confirmatory testing, withhold all live attenuated vaccines 1
Don't assume normal thymus on imaging excludes SCID: Some SCID forms (CD3δ deficiency, coronin 1A deficiency) can have normal-appearing thymus 5
Don't use term "variant SCID": This term has no counterpart in immunology specialty care and should be avoided 1
Performance Metrics
- Positive predictive value: Approximately 2-10% for SCID detection 4, 7
- Sensitivity: Extremely high—TREC assay detects SCID with remarkable sensitivity 3
- Incidence: Approximately 1 in 50,000-130,000 births based on screening data 4, 7
- Secondary findings: Non-SCID TCL detected in approximately 1 in 10,000 newborns (43% of positive detections) 4